Clinical Trials · NCT00884715

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Name: Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 1/Phase 2Octreotide

Phase: Phase 1/Phase 2
Recruitment status: Terminated
Sponsor: Endo USA Inc., a Keenova Therapeutics Company
Enrollment: 10
Start date: Jul 2009
Locations: 3 sites, United States
Primary endpoint: Assess the effects of 1 or 2 implants on carcinoid syndrome symptoms of flushing and diarrhea

View Octreotide compound reference